Botulinum-A toxin detrusor and sphincter injection in treatment of overactive bladder syndrome: Objective outcome and patient satisfaction

European Urology

Volumn 48, Issue 6, 2005, Pages 984-990

  Schulte Baukloh, Heinrich ^a   Weiß, Catarina ^a   Stolze, Thomas ^a   Herholz, Jaqueline ^a   Stürzebecher, Burkard ^a   Miller, Kurt ^a   Knispel, Helmut H ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Botox; Botulinum toxin; Detrusor; Detrusor overactivity; OAB; Overactive bladder syndrome

Indexed keywords

BOTULINUM TOXIN A;

ADULT; AGED; ARTICLE; BLADDER CAPACITY; CLINICAL ARTICLE; CONTROLLED STUDY; DETRUSOR MUSCLE; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; HUMAN; MALE; OUTCOMES RESEARCH; OVERACTIVE BLADDER; PATIENT SATISFACTION; PRIORITY JOURNAL; QUESTIONNAIRE; SPHINCTER; TREATMENT OUTCOME; URINARY FREQUENCY; URODYNAMICS;

ADULT; AGED; AGED, 80 AND OVER; BOTULINUM TOXIN TYPE A; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRALESIONAL; MALE; MIDDLE AGED; MUSCLE, SMOOTH; PATIENT SATISFACTION; PROSPECTIVE STUDIES; RECOVERY OF FUNCTION; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; URINARY INCONTINENCE; URODYNAMICS;

EID: 27844538452     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2005.06.021     Document Type: Article

References (32)

1. P. Abrams, L. Cardozo, M. Fall, D. Griffiths, P. Rosier, and U. Ulmsten The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society Neurourol Urodyn 21 2002 167 178
2. P. Abrams, C.J. Kelleher, L.A. Kerr, and R.G. Rogers Overactive bladder significantly affects quality of life Am J Manag Care 6 suppl. 2000 580 590
3. W.F. Stewart, J.B. Van Rooyen, G.W. Cundiff, P. Abrams, A.R. Herzog, and R. Corey Prevalence and burden of overactive bladder in the United States World J Urol 20 2003 327 336
4. I. Milsom, W. Stewart, and J. Turoff The prevalence of overactive bladder Am J Manag Care 6 suppl. 2000 565 573
5. I. Milsom, P. Abrams, L. Cardozo, R.G. Roberts, J. Thuroff, and A.J. Wein How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study BJU Int 87 2001 760 766
6. A. Elbadawi, S.V. Yalla, and N.M. Resnick Structural basis of geriatric voiding dysfunction. III. Detrusor overactivity J Urol 150 1993 1668 1680
7. Ouslander JG. Lower urinary tract disorders in the elderly female. In: Raz S, editor. Female Urology, Philadelphia: Saunders, 219-30.
8. K.E. Andersson, and C.R. Chapple Oxybutynin and the overactive bladder World J Urol 19 2001 319 323
9. H. Madersbacher, and G. Murtz Efficacy, tolerability and safety profile of propiverine in the treatment of the overactive bladder (non-neurogenic and neurogenic) World J Urol 19 2001 324 335
10. R.A. Appell, P. Abrams, H.P. Drutz, P.E. Van Kerrebroeck, R. Millard, and A. Wein Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine World J Urol 19 2001 141 147
11. F. Haab, L. Stewart, and P. Dwyer Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder Eur Urol 45 2004 420 429
12. E.S. Rovner, and A.J. Wein Update on overactive bladder: pharmacologic approaches on the horizon Curr Urol Rep 4 2003 385 390
13. Y.E. Yarker, K.L. Goa, A. Fitton, and Oxybutynin A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability Drugs Aging 6 1995 243 262
14. P. Herbison, J. Hay-Smith, G. Ellis, and K. Moore Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review BMJ 326 2003 841 848
15. D.D. Dykstra, A.A. Sidi, A.B. Scott, J.M. Pagel, and G.D. Goldish Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients J Urol 139 1988 919 922
16. B. Schurch, M. Stohrer, G. Kramer, D.M. Schmid, G. Gaul, and D. Hauri Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results J Urol 164 2000 692 697
17. M. Chancellor, M. O'Leary, J. Erickson, T. Cannon, C. Chermansky, and W.W. Leng Successful use of bladder botulinum toxin injection to treat refractory overactive bladder J Urol 169 suppl. 4 2003 351
18. D.E. Rapp, A. Lucioni, E.E. Katz, R.C. O'Connor, G.S. Gerber, and G.T. Bales Use of botulinum-A toxin for the treatment of refractory overactive bladder symptoms: an initial experience Urology 63 2004 1071 1075
19. H.C. Kuo Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents Urology 63 2004 868 872
20. D.M. Schmid, B. Schurch, H. John, and D. Hauri Botulinum toxin injections to treat overactive bladder Eur Urol 2 suppl. 3 2004 131
21. Kessler TM, Danuser H, Schumacher M, Studer UE, Burkhard FC. Botulinum A toxin injections into the detrusor: An effective treatment in idiopathic and neurogenic detrusor overactivity? Neurourol Urodyn Mar 3 [online], 2005.
22. M. Harper, R.B. Popat, R. Dasgupta, C.J. Fowler, and P. Dasgupta A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity BJU Int 92 3 2003 Aug 325 326
23. H. Schulte-Baukloh, T. Michael, B. Sturzebecher, and H.H. Knispel Botulinum-a toxin detrusor injection as a novel approach in the treatment of bladder spasticity in children with neurogenic bladder Eur Urol 44 2003 139 143
24. J.S. Uebersax, J.F. Wyman, S.A. Shumaker, D.K. McClish, and J.A. Fantl Short forms to assess life quality and symptom distress for urinary incontinence in women: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Continence Program for Women Research Group Neurourol Urodyn 14 1995 131 139
25. N. Black, J. Griffiths, and C. Pope Development of a Symptom Severity Index and a Symptom Impact Index for stress incontinence in women Neurourol Urodyn 15 1996 630 640
26. J.M. Choe, K. Ogan, and S. Bennett Antibacterial mesh sling: a prospective outcome analysis Urology 55 2000 515 520
27. A. Reitz, M. Stohrer, G. Kramer, G. Del Popolo, E. Chartier-Kastler, and J. Pannek European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity Eur Urol 45 2004 510 515
28. M.B. Chancellor, and C.P. Smith A single surgeon's six-year experience with botulinum toxin into the bladder and urethra J Urol 171 suppl. 2004 138
29. G.A. Digesu, A. Hutchings, S. Salvatore, L. Selvaggi, R. Milani, and V. Khullar Pressure flow study: a useful diagnostic test of female lower urinary tract symptoms Neurourol Urodyn 23 2004 104 108
30. W. Jost Pelvic floor and gastrointestinal uses P. Moore M. Naumann Handbook of Botulinum Toxin treatment 2003 Blackwell Science 360 367
31. H.C. Kuo Botulinum A toxin urethral injection for the treatment of lower urinary tract dysfunction J Urol 170 2003 1908 1912
32. J.J. Wyndaele, and S.A. Van Dromme Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity Spinal Cord 40 2002 599 600